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| INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children.
1 Over the past decades, survival rates increased tremendously to a 5-year overall survival of >90% 2,3 due to more insight in the pathogenesis of ALL and optimized treatment strategies. 4 The potential drawback of these treatment regimens is the burden of toxic effects. A severe and well-described complication in ALL patients is venous thromboembolism (VTE). 5 Reported incidences of VTE in childhood ALL varies from 1.1% to 36.7%. 6, 7 The overall mortality rate in ALL patients as a result of VTE varies between 0% and 4.8%. 6 A substantial proportion of VTE in ALL is due to cerebral venous sinus thrombosis (CVST) with a reported mortality between 0% and 28%. [8] [9] [10] [11] Morbidity includes recurrent thrombosis, neurologic changes, catheter removal, bleeding due to antithrombotic agents, and the development of the postthrombotic syndrome. [12] [13] [14] 15 Furthermore, VTE can lead to suboptimal ALL therapy, due to the necessity to interrupt, delay, or even discontinue chemotherapy, and thereby to inferior disease outcomes. 16 Mechanisms underlying the increased VTE risk in ALL are not completely understood. Previous studies have shown that the disease itself, as well as treatment components, and patient characteristics, such as age, and thrombophilia, may contribute to a prothrombotic state. 6, 8, [12] [13] [14] 17, 18 The highest VTE risk arises in the first weeks of ALL treatment, especially during the use of asparaginase, in combination with corticosteroids. 13, 17, 19 Asparaginase is one of the most important risk factors for VTE, as it can induce coagulation disorders by decreasing natural anticoagulant proteins such as antithrombin (AT), protein C and protein S. However, it is also an essential component in modern ALL treatment, as insufficient exposure to asparaginase was shown to lead to decreased survival. 3, 16, 20 A better understanding of specific clinical risk factors for VTE during asparaginase treatment in ALL patients will be helpful to identify patients, in whom preventive measures might be beneficial, thereby improving the quality of ALL treatment.
The aim of this study is to assess the risk of symptomatic VTE during ALL treatment and identify clinical risk factors for VTE during asparaginase treatment in a large, well-defined large cohort of children with ALL treated in the Dutch Childhood Oncology Group (DCOG) ALL-10 study, using a case-control design. In addition, we explored the effect of the development of VTE on the event free survival (EFS).
| METHODS

| Study population
We retrospectively analyzed children with ALL treated in the DCOG 
| Treatment
All children received the same induction chemotherapy containing prednisone 60 mg/m 2 /day (days 1-28), and eight doses of native E.coli asparaginase (5000 IU/m 2 per dose) every 3 days (Figure 1 ).
Patients were stratified into three risk groups after induction treatment: standard risk, medium risk, and high risk. Medium risk patients received intensification therapy containing dexamethasone (6 mg/ m 2 /day, 5 days every 3 weeks) and PEG-asparaginase (2500 IU/m 2 ,
doses in 30 weeks).
In all patients, a CVC was placed upon treatment initiation. None of the patients received low-molecular-weight heparin (LMWH) or AT supplementation routinely as thrombosis prophylaxis during ALL treat- We did not include patients with incidentally found asymptomatic VTE, to avoid introduction of bias as result of missed asymptomatic thrombi. Detailed patient and treatment information was
Essentials
• Venous thromboembolism (VTE) is a common complication in pediatric acute lymphoblastic leukemia (ALL).
• This Dutch study identified incidence and risk factors for VTE.
• 7.6% of patients developed VTE, of which 44.1% were cerebral venous sinus thrombosis (CVST Part of the children with VTE were tested for congenital thrombophilia, eg, Factor V Leiden or prothrombin G20210A mutation, or a reduced AT, protein C or S level according to local protocol.
| Statistical analysis
VTE was expressed as percentage. Differences between children with and without VTE were calculated using Mann-Whitney U, Full treatment schedules are included for the induction cycles Protocol IA + IB and M. For the SR, MR and HR protocol, only the use of steroids and asparaginase are listed, while other treatment agents are not multivariable conditional logistic regression models were estimated to take into account the case-control design models. 23 Results are expressed as odds ratio (OR) with corresponding 95% confidence intervals (CI).
The effect of VTE on EFS (defined as non-response, relapse, secondary malignancy, or death), was investigated by using an multi- 
| RESULTS
| Patients and VTE events
VTE events occurred in 59 of 778 included children (7.6%) during treatment in the ALL-10 study. Of 59 children with VTE, 26 (44.1%) experienced CVST, 12 patients (20.3%) DVT of the leg, three patients (5.1%) PE, and 18 patients (30.5%) ULVT or CVC-related thrombosis. None of these patients had previously experienced VTE (Table 1) . Forty of 59 children were tested for congenital thrombophilia; in only two children, thrombophilia was found (one heterozygous prothrombin G20210A mutation, one heterozygous Factor V Leiden mutation). 
| VTE events and ALL treatment
| Identification of clinical risk factors for VTE in the case control study
Baseline characteristics for cases and controls are shown in Table 1 .
Univariate conditional logistic regression analysis showed that age as a dichotomous variable (age ≥7) ALL subtype (T-ALL) and ALL medium risk group were statistically significantly associated with VTE (Table 2 ). In a multivariable conditional logistic regression analysis age and ALL subtype remained statistically significantly associated with VTE. Of all VTE, 24.1% occurred in patients aged 1-5 years, 48.3% in patients aged 6-12 years and 27.6% in patients aged ≥13 years.In a univariate conditional logistic regression subanalysis for CVST, including age, ALL subtype, and ALL risk group, age ≥7 years and ALL medium risk group were the only significantly associated risk factor for CVST (Table 3) . In a conditional multivariable logistic regression analysis none of these factors remained statistically significantly associated with CVST. Age distribution in patients with CVST was 16%, 56%, and 28% in age groups 1-5, 6-12, and ≥13 years, respectively.
TA B L E 1 Patient characteristics
Cases with VTE (N = 59)
Controls without VTE (N = 118)
Male, n (%) 35 
| Treatment and outcome of VTE
Median follow-up of the 59 VTE patients was 4.9 years (range 0.7-9.6 years). Fifty-three patients were treated with LMWH. Three patients with CVST did not receive LMWH due to concurrent bleeding.
In one child with CVC related VTE the CVC was removed without anticoagulant treatment, and one patient had successful local lowdose thrombolytic therapy. In one patient, the reason for withhold- The patient with prophylactic LMWH died due to recurrent VTE (PE).
In 25 of 59 patients (42.4%), VTE occurrence led to ALL treatment protocol changes, such as delay or premature cessation of asparaginase therapy (n = 10), intrathecal therapy (n = 1), or both asparaginase and intrathecal therapy (n = 12). Details of withheld therapy doses were not retrieved. In one patient, only dexamethasone was cancelled, and in one patient treatment adjustments were unknown.
Eight of 59 patients (13.6%) with VTE died, but none directly due to the initial thrombotic event, compared to 13 of 118 control patients (11%). In the CVST subgroup, no patients died directly due to their thrombosis. Overall, four of 26 patients (15.4%) with CVST died, compared to three of 52 control CVST patients (5.8%).
In patients with CVST, acquired permanent disability as a result of the CVST was present in nine patients (34.6%). Most common was symptomatic epilepsy. Two patients had symptomatic epilepsy, focal motor deficits and cognitive disabilities. One patient had focal motor deficits. Six patients (30.8%) had symptomatic epilepsy and were treated with anti-epileptic treatment for more than 1 year.
| VTE and outcome of ALL
Multivariable Cox model showed no association between the occurrence of all types of VTE and event free survival (HR = 1.4, 95% CI 0.69-2.72.
| DISCUSSION
This study demonstrated that VTE occurred in 7.6% of children during ALL treatment. Multivariable analyses using a case-control design showed that age ≥7 years was a main risk factor for VTE, thus confirming other studies. 24, 25 Accordingly, it is recommended to include age in preventive strategies for VTE during ALL treatment. An analysis of the developmental hemostatic system showed a relative protective effect against VTE in young infants, compared with adults, with decreased levels of several critical procoagulant factors and increased levels of certain natural anticoagulants. 26 As the hemostatic system matures with increasing age in children, this may also increase their baseline VTE risk towards the level of young adults. Older children may, therefore, represent a subgroup of pediatric ALL patients in whom thromboprophylaxis with LMWH might be beneficial, and safe. 27, 28 FFP or antithrombin supplementation have been described, but results on efficacy are inconsistent and inconclusive. [29] [30] [31] [32] [33] [34] In the univariate conditional logistic regression model, T-ALL subtype (OR 3.75; 95% CI 1.40-10.04) and ALL medium risk group (OR 2.40; 95% CI 1.17-4.89) were also significantly associated with VTE in addition to age. In the multivariable analysis T-ALL subtype appeared to be an independent risk factor, as in the study of Giordano. That study described higher thrombin levels in T-ALL patients. 35 ALL medium risk group was no longer significantly associated with VTE.
In concordance with other studies, asparaginase therapy is an important risk factor for VTE, during ALL treatment. 7, 15, 18 In our study, a majority of patients received asparaginase prior to VTE.
Although the standard and high risk protocols both include one or more singular doses of asparaginase, it is likely that the repetitive and long-term use of asparaginase in the induction cycles and medium risk protocol particularly predispose to a high VTE risk. This is in line with previous studies that demonstrated that length of exposure to, but not the dosages of asparaginase correlates with VTE risk. 7, 8 In addition, a previous study showed no correlation between the level of asparaginase activity and the occurrence of VTE.
36
We also observed that CVST occurred very shortly after administration of asparaginase therapy in comparison with other types of VTE.
This might be an explanation for the observation that CVST events occurred significantly earlier during treatment compared with other types of VTE. It is possible that patients with CVST represent a subgroup of patients at highest risk of VTE. However, specific risk factors and mechanisms explaining the predisposition for CVST during ALL treatment are still unclear. 10, 37 One risk factor might be the simultaneous administration of steroids as combination therapy (asparaginase and steroids) occurred twice as much in patients with CSVT than in patients with other VTE.
11
In over one-third (40%) of the VTE patients, VTE led to dose adjustments or interruption of asparaginase therapy. Asparaginase is a central component of ALL treatment, and not completing the full total dosage, could lead to a significantly worse outcome. 16 In our study, no statistical significance association was found between occurrence of VTE and EFS. It is ambiguous if reintroduction of asparaginase after VTE is safe. Two studies described reintroduction of asparaginase, in which most patients received LMWH prophylaxis and no recurrent thrombosis occurred. 38, 39 However, another study described a high VTE recurrence rate, despite anticoagulant therapy. 18 Therefore, the efficacy and safety of thromboprophylaxis during ALL treatment remain unclear, and future studies are required for further assessment.
In the meantime, identifying risk factors and those patients at highest risk may help to prepare such studies.
Although VTE events were collected prospectively, complete data retrieval was not possible for some variables, such as withheld therapy after VTE diagnosis. Although treatment protocols were standardized in the involved treatment centers, differences in care and awareness may have influenced VTE incidence. Moreover, we used a case-control design instead of the entire ALL-10 cohort for our analysis; despite using a 1:2 ratio for cases and controls, this may have affected the power of our results. In addition, we did not systemically study the presence of congenital thrombophilia in the ALL patients.
In conclusion, age ≥7 years at diagnosis and T-ALL subtype are the main risk factors for VTE in children with ALL treated within a well-defined setting including steroids and asparaginase. This underlines the importance of preventive strategies in those children with ALL at high-risk for VTE.
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